Related by context. All words. (Click for frequent words.) 77 reinfarction 76 nonfatal MI 75 definite stent thrombosis 75 periprocedural 74 recurrent VTE 73 cerebrovascular events 73 MACCE 73 myocardial infarction MI 73 nonfatal myocardial infarction 72 myocardial infarction stroke 72 VT VF 72 repeat revascularization 71 symptomatic VTE 71 nonfatal stroke 71 severe neutropenia 70 arterial thromboembolic events 70 recurrent myocardial infarction 70 binary restenosis 70 thromboembolic 70 coronary revascularization 70 TEAEs 69 postintervention 69 myocardial infarctions 69 cardiovascular hospitalizations 69 resuscitated cardiac arrest 69 recurrent ischemia 69 HF hospitalization 69 cerebrovascular accidents 68 hemorrhagic complications 68 thromboembolic events 68 nondiabetic patients 68 systemic embolism 68 rebleeding 68 underwent resection 68 Stent thrombosis 68 thromboses 68 XIENCE V PROMUS Stent 67 recurrent venous thromboembolism 67 proximal DVT 67 stent thromboses 67 refractory ischemia 67 virologic failure 67 LV dysfunction 67 myocardial infarction 67 fibrinolysis 67 postoperative mortality 67 cerebral vasospasm 67 composite endpoint 67 paroxysmal AF 67 thrombotic events 67 stent implantation 66 cardiovascular hospitalization 66 MIs 66 intravitreal injections 66 events MACE 66 ventricular tachycardia VT 66 p = NS 66 advanced adenoma 66 recurrent DVT 66 valvular disease 66 CCyR 66 inhospital 66 cerebrovascular accident 66 prolonged QT interval 66 revascularizations 66 Hypotension 66 interquartile range 66 postoperative complication 66 VTEs 66 discontinuations due 66 carotid stenosis 66 pericardial effusion 66 biochemical recurrence 66 timepoints 66 PSADT 66 thromboembolism 66 XIENCE V demonstrated 66 β blockers 66 de ath 66 Thrombolysis 66 severe hypoglycemic 66 target vessel revascularization 66 Postoperative complications 66 colorectal adenoma 66 unstable angina pectoris 66 thromboembolic complications 66 P = .# 66 biochemical relapse 66 androgen deprivation 65 severe exacerbations 65 morphometric vertebral fractures 65 syncopal 65 glycated hemoglobin levels 65 recanalization 65 ischemic cardiomyopathy 65 paclitaxel eluting stents 65 HSCT 65 infarctions 65 Kaplan Meier analysis 65 % CI #.#-#.# [007] 65 pCR 65 reintervention 65 angiographic restenosis 65 COPD exacerbation 65 symptomatic intracranial 65 secondary efficacy endpoint 65 perioperative mortality 65 asthma exacerbation 65 ventricular tachyarrhythmia 65 posttransplant 65 death reinfarction 65 virological response 65 Kaplan Meier estimates 65 androgen suppression 65 IELT 65 upper gastrointestinal bleeding 65 DES implantation 65 ventricular arrhythmia 65 Events MACE 65 acute myocardial infarctions 65 perioperative complications 65 locoregional recurrence 65 radical nephrectomy 65 macrovascular events 65 nadroparin 65 postoperative complications 65 pyelonephritis 65 salmeterol HFA MDI 64 Erythropoietic therapies may 64 ischemia driven 64 ejection fractions 64 cryptogenic stroke 64 underwent CABG 64 subtrochanteric 64 % CI #.#-#.# [003] 64 troponin T 64 paroxysmal atrial fibrillation 64 vertebral fracture 64 NIHSS score 64 hyperacute 64 atrioventricular block 64 variceal bleeding 64 proliferative retinopathy 64 non valvular atrial 64 confidence interval CI 64 LVEF 64 stroke transient ischemic 64 Operative mortality 64 NATRECOR R 64 intraventricular hemorrhage 64 eplerenone 64 ALT flares 64 nonischemic 64 LVSD 64 oral allopurinol 64 intracerebral hemorrhage 64 neurologic sequelae 64 ICD implantation 64 Major Adverse Cardiac 64 CR nPR 64 nadolol 64 intracerebral hemorrhages 64 confirmed thrombotic cardiovascular 64 endophthalmitis 64 progression TTP 64 intima media thickness 64 Crohn Disease Activity 64 acute myocardial infarction AMI 64 postoperative AF 64 endometrial carcinoma 64 TAXUS Express Stent 64 HBeAg seroconversion 64 thrombolytic therapy 64 target lesion revascularization 64 lacunar 64 virologic response 64 undergoing CABG 64 NSTEMI 64 timepoint 64 colectomy 64 QTc 63 tumor recurrence 63 retransplantation 63 evaluable subjects 63 EBRT 63 tirofiban 63 Myocardial infarction 63 renal dysfunction 63 sirolimus stent 63 sirolimus eluting stents 63 EDSS scores 63 perioperatively 63 infarcts 63 ATACAND 63 aneurysmal subarachnoid hemorrhage 63 doxorubicin docetaxel 63 radial artery grafts 63 STEMI patients 63 ARCOXIA 63 reoperations 63 HbA 1c levels 63 gout flares 63 acute STEMI 63 laboratory abnormalities 63 DAS# remission 63 adrenalectomy 63 neurologic complications 63 pulmonary resection 63 Febrile neutropenia 63 subclinical hypothyroidism 63 aneurysm rupture 63 ischemic lesions 63 confidence interval #.#-#.# 63 everolimus eluting stents 63 MADRS score 63 NATRECOR ® 63 alteplase 63 thrombotic complications 63 platelet reactivity 63 mL/min/#.# m 2 63 ximelagatran 63 nonvertebral fractures 63 peri procedural 63 ruptured aneurysms 63 EXJADE 63 PRADAXA #mg 63 SCr 63 recurrent wheezing 63 distant metastasis 63 CVD mortality 63 PASI scores 63 gastrointestinal perforation 63 ischemic complications 63 left ventricular dysfunction 63 cytogenetic response 63 chlorambucil 63 tumor regressions 63 cytopenias 63 PSA nadir 63 chronic GVHD 63 microvascular complications 63 mg kg dose 63 adenomatous polyps 63 postprocedure 63 TAVR 63 invasive aspergillosis 63 sustained ventricular tachycardia 63 cerebral infarction 63 recurrent atrial fibrillation 63 pT3 63 % CI #.#-#.# [006] 63 complete cytogenetic response 63 achieved ACR# 63 recurrent stroke 63 FluCAM arm 63 subarachnoid hemorrhages 63 noncardiac 63 asymptomatic carotid stenosis 63 carotid IMT 63 primary patency 63 undergoing coronary artery 63 TAXUS p value 63 tumor lysis syndrome 63 symptomatic intracranial hemorrhage 63 vasospasm 63 anterior uveitis 63 infarct size 63 corrected QT interval 62 diameter stenosis 62 microalbuminuria 62 tachyarrhythmias 62 nonfatal myocardial infarction MI 62 carotid endarterectomy 62 rehospitalization 62 adjunctive placebo 62 QRS duration 62 cardiogenic shock 62 tumor resection 62 hypoglycemic episodes 62 mcg BID 62 graft occlusion 62 pacemaker implantation 62 spinal cord compression 62 cardioembolic stroke 62 IOP lowering 62 thrombocytopenic 62 liver resection 62 CHD CVD 62 prospectively defined 62 Median survival 62 p = #.# [003] 62 prespecified secondary 62 certolizumab 62 generalized edema 62 intraoperative complications 62 rFVIIa 62 malignant neoplasm 62 postoperative atrial fibrillation 62 histologic subtype 62 neurologic progression 62 preintervention 62 endarterectomy 62 DAPT 62 fatal myocardial infarction 62 advanced adenomas 62 median PFS 62 ischemic strokes 62 hemodynamic instability 62 histologically confirmed 62 hematologic toxicity 62 hepatectomy 62 posttreatment 62 methotrexate monotherapy 62 chemoradiotherapy 62 Index CDAI 62 ipsilateral 62 atherothrombotic disease 62 revascularization procedures 62 atherothrombotic 62 Fontan procedure 62 Pulmonary embolism 62 leucopenia 62 Treatment emergent adverse 62 hypomagnesemia 62 lymphocytosis 62 generalized seizures 62 seroconversion 62 stent thrombosis 62 dalteparin 62 cerebral infarctions 62 ribavirin therapy 62 carotid artery stenting CAS 62 sirolimus eluting stent 62 lopinavir r arm 62 CMV infection 62 Recurrences 62 postop 62 torsades de pointes 62 curative resection 62 hepatic resection 62 revascularisation 62 angiographic outcomes 62 carotid artery blockage 62 variceal 62 severe hypoglycemia 62 stroke myocardial infarction 62 hypoperfusion 62 NNT = 62 NMIBC 62 beta blocker therapy 62 tenecteplase 62 tolvaptan 62 preoperative PSA 62 deep venous thromboses 62 PAOD 62 underwent surgical resection 62 endometrial hyperplasia 62 hepatorenal syndrome 62 NYHA Class II 62 coronary stenosis 62 systolic dysfunction 62 luminal diameter 62 Hemorrhagic strokes 62 ECG abnormalities 62 SUVmax 62 empyema 62 symptom onset 62 carotid revascularization 62 PREZISTA r arm 61 reperfusion therapy 61 bypass graft CABG surgery 61 mcg QD 61 lumbar spine BMD 61 octreotide LAR 61 pulmonary dysfunction 61 Thrombocytopenia 61 endometrial thickness 61 SLNB 61 leukocyte count 61 venous thromboembolic 61 chorioamnionitis 61 lymphadenectomy 61 ST elevation myocardial 61 percutaneous intervention 61 hematologic adverse 61 T2DM 61 ischemic stroke 61 prostate cancer CaP 61 PLX STROKE targeting 61 ventricular fibrillation VF 61 bronchopulmonary dysplasia 61 oxycodone CR 61 renal flares 61 LV ejection fraction 61 intracranial hemorrhage ICH 61 HBeAg negative patients 61 venous thrombotic events 61 liver decompensation 61 carotid endarterectomy CEA 61 acute aortic dissection 61 radical prostatectomy RP 61 ertapenem 61 hemodynamically significant 61 femoral shaft fracture 61 apnea hypopnea 61 cardiac tamponade 61 cardiac dysfunction 61 annualized relapse 61 asystole 61 hypoglycemic events 61 transaminase elevations 61 QTc prolongation 61 adenoidectomy 61 fatal arrhythmic 61 incidence ≥ 61 tapentadol ER 61 TAXUS Stent 61 bolus dose 61 patients undergoing CABG 61 torsade de pointes 61 myocardial infarctions MI 61 myocardial infarctions MIs 61 carotid artery stenosis 61 flutamide 61 VAD implantation 61 decompensated heart failure 61 anastomotic leak 61 nonoperative treatment 61 malperfusion 61 stenoses 61 APTIVUS r 61 acute decompensation 61 debulking surgery 61 serum aminotransferase levels 61 pulmonary emboli 61 CMV disease 61 Anaphylactic reactions 61 HBeAg negative 61 CC genotype 61 Infusion Reactions Severe 61 pT2 61 revascularization procedure 61 external genital lesions 61 SVR# 61 graft dysfunction 61 DAS# CRP 61 Subarachnoid hemorrhage 61 ischemic cerebrovascular 61 cytoreduction 61 rt PA 61 Percutaneous Coronary Intervention 61 spontaneous preterm birth 61 atherothrombotic events 61 arterial occlusion 61 CrCl 61 NYHA class 61 neoadjuvant 61 CYPHER Stent 61 Complication rates 61 mediastinitis 61 artery stenosis 61 recurrent glioblastoma multiforme 61 CHD mortality 61 transcatheter closure 61 nonsignificant 61 mg/m2 dose 61 ALT elevation 61 MMSE score 61 antithrombotic therapy 61 workhorse lesions 61 extrapyramidal symptoms 61 extubation 61 relapsed MM 61 KIF6 carriers 61 HBeAg positive patients 61 postdischarge 61 events TEAEs 61 #.#/#.# mmHg [001] 61 femoral neck fracture 61 multivariate adjustment 61 TURBT 61 desvenlafaxine succinate 61 plasma cortisol 61 nonobstructive CAD 61 parathyroidectomy 61 hypoglycaemic episodes 61 4mg/kg 61 sustained virological response 61 neutrophil counts 61 venous thromboembolism 61 nonvertebral fracture 61 NSTE ACS 61 ICD shocks 61 EDSS score 61 pneumonectomy 61 STRIDE PD 61 #mg BID [001] 61 postoperative bleeding 61 ischemic 61 elevated LDH 61 CIMZIA TM certolizumab pegol 61 confirmed CCyR 61 postoperatively 61 transurethral resection 61 ug dose 61 metastatic malignant 61 deep vein thromboses 61 intravenous diuretics 61 sternal wound infections 61 EURIDIS 61 REYATAZ r arm 61 radiographic progression 61 carotid intima media 61 QTc intervals 61 fondaparinux 61 chemoradiation therapy 61 Hemorrhagic stroke 61 coronary intervention 61 CIN3 60 cardiovascular mortality 60 clinically localized prostate 60 QTcF 60 Carotid Revascularization Endarterectomy vs. 60 thrombolysis 60 CTEPH 60 pulmonary artery banding 60 malignant neoplasms 60 distant metastases 60 virological failure 60 alanine aminotransferase 60 nonmelanoma skin cancer 60 nonmetastatic 60 underwent coronary angiography 60 Baseline characteristics 60 liver metastasis 60 atrioventricular valve 60 neurologic outcomes 60 hippocampal atrophy 60 fragility fracture 60 noncardiac surgery 60 % Confidence Interval 60 virologic breakthrough 60 noncarriers 60 autonomic dysfunction 60 afib 60 intracerebral 60 Myocardial Infarction Study 60 mm Stent 60 pathologic diagnosis 60 multivariate Cox 60 % CI #.#-#.# [001] 60 undergoing coronary angiography 60 antiplatelet drugs 60 fraction LVEF 60 baseline HbA1c 60 adenotonsillectomy 60 HAM D# scores 60 microbleeds 60 sinus node dysfunction 60 asymptomatic PAD 60 receiving ISENTRESS 60 bacteriuria 60 HbA1c levels 60 intravenous bisphosphonates 60 serum phosphate 60 paroxysmal 60 neurodevelopmental impairment 60 Doxil ® 60 unstable angina UA 60 estimated glomerular filtration 60 Ischemic 60 intracerebral hemorrhage ICH 60 thrombophilia 60 VTE 60 MIRAPEX 60 moderately emetogenic 60 onset atrial fibrillation 60 cryptogenic 60 atheroma volume 60 vasogenic edema 60 atrial tachyarrhythmias 60 pulmonary embolism PE 60 venous thromboembolic events 60 clodronate 60 bilateral TKA 60 anticoagulation therapy 60 aneurysm ruptures 60 euthyroid 60 intracranial stenosis 60 pericardial effusions 60 nodal metastases 60 POAG 60 fulminant 60 CABG 60 AGILECT R 60 thyrotropin levels 60 plasma uric acid 60 recurrent ischemic stroke 60 Scale EDSS score 60 response pCR 60 symptomatic carotid stenosis 60 pheochromocytoma 60 ALND 60 systolic hypertension 60 haematologic 60 surgical debulking 60 #mg QD [002] 60 Primary endpoints 60 mcg albinterferon alfa 2b 60 varices 60 Torsades de Pointes 60 CYPHER ® 60 lowest tertile 60 pelvic lymphadenectomy 60 Taxus Stent 60 KRAS mutations occur 60 acute ischemic 60 insulin detemir 60 etiologic 60 % CI #.#-#.# [008] 60 gastrointestinal bleeds 60 revascularization 60 repeat paracentesis 60 myocardial ischemia 60 PegIFN RBV 60 hemorrhagic strokes 60 defibrillator CRT D 60 neutropenia dehydration dyspnea 60 symptomatic pulmonary embolism 60 post thrombotic syndrome 60 thromboprophylaxis 60 lymphopenia 60 Scale EDSS 60 venous blood clots 60 aged ≥ 60 ribavirin RBV 60 T2 lesions 60 cisplatin vinorelbine 60 ductal cancer 60 abacavir lamivudine 60 angiographically 60 Severe hypoglycemia 60 ADHF 60 conjunctival hyperemia 60 preoperative chemotherapy 60 T1c 60 infarction 60 sustained virologic response 60 macroalbuminuria 60 carotid atherosclerosis 60 detectable HCV RNA 60 nonfatal pulmonary embolism 60 TP# mutations 60 eptifibatide 60 evaluable 60 renal insufficiency 60 remission CR 60 liver transplant recipients 60 RE LY ® 60 thrombus aspiration 60 symptomatic atrial fibrillation 60 ARIXTRA 60 treatment emergent adverse 60 #mmHg [001] 60 reoperation 60 Folfox 60 hyperglycaemia 60 GP IIb IIIa inhibitors 60 biologic DMARD 60 Toxicities 60 adjuvant tamoxifen 60 intraocular inflammation 60 hepatic failure 60 drug eluting stent implantation 60 hepatotoxicity 60 candidemia 60 prespecified 60 pulmonary exacerbation 60 advanced neoplasia 60 haemorrhagic strokes 60 hepatic metastases 60 urate lowering therapy 60 Y BOCS 60 cytogenetic responses 60 univariate analysis 60 febrile neutropenia 60 metastatic malignant melanoma 60 methacholine challenge 60 Stenting Trial CREST 60 corticosteroid therapy 60 concomitant antibiotics 60 prospective multicenter study 60 ventricular dysfunction 60 landmark ATHENA trial 60 silent ischemia 60 creatine kinase MB 60 acute coronary syndromes ACS 60 artery occlusion 60 bacteraemia 60 hypophosphatemia 60 perioperative morbidity 59 asymptomatic AF 59 periprocedural MI 59 ExTRACT TIMI 59 NIHSS 59 contrast induced nephropathy 59 highest tertile 59 leiomyomas 59 generalized tonic clonic seizures 59 seropositivity 59 prospectively stratified 59 lobectomy 59 pathologic fracture 59 neointimal hyperplasia 59 stent binary restenosis 59 mesotheliomas 59 Restenosis 59 overt nephropathy 59 PSVT 59 undetectable HCV RNA 59 recurrent malignant glioma 59 Venous thromboembolism 59 Severe acneform rash 59 diagnostic angiography 59 ventricular tachyarrhythmias 59 hours postdose 59 mCi kg 59 cilostazol 59 posaconazole 59 Cypher Stent 59 sd = 59 #Gy 59 RLAI 59 reinterventions 59 wound dehiscence 59 Unstable Angina 59 T1DM 59 lispro 59 subarachnoid hemorrhage SAH 59 segment binary restenosis 59 intracerebral haemorrhage 59 Free Survival PFS 59 angiographic follow 59 apnea hypopnea index 59 Ishak fibrosis score 59 patients undergoing percutaneous 59 creatinine clearance 59 tamponade 59 lung resection 59 QTc interval 59 invasive carcinomas 59 Score TOS 59 leukoencephalopathy 59 HGPIN 59 aplastic anemia AA 59 imipenem 59 neutropaenia 59 coronary artery occlusion 59 DLTs 59 symptomatic intracerebral hemorrhage 59 levodopa therapy 59 seroprotection 59 ischemic cardiovascular 59 elevated IOP 59 mg QD 59 thrombocytosis 59 zotarolimus eluting stent 59 events SAEs 59 antiplatelet medication 59 acute ischemic stroke 59 Hb A1C 59 postsurgical 59 acute coronary 59 CDI recurrence 59 Pegylated Liposomal Doxorubicin 59 infective endocarditis 59 postoperative chemotherapy 59 hip BMD 59 stenting 59 neutropenic fever 59 salmeterol fluticasone 59 neonatal morbidity 59 Intracerebral hemorrhage 59 nontraumatic 59 allogeneic HSCT 59 oral diclofenac 59 prior chemotherapy regimens 59 achieved CCyR 59 Ischemic stroke 59 cystectomy 59 hypoxemia 59 clinically evaluable patients 59 postoperative morbidity 59 radical retropubic prostatectomy 59 pretest probability 59 depressive symptomatology 59 thyroid carcinoma 59 multivariable analysis 59 MGUS 59 activated partial thromboplastin 59 coronary revascularisation 59 XIENCE V vs. 59 haematological toxicity 59 dual antiplatelet therapy 59 ancrod 59 severe rotavirus gastroenteritis 59 intravenous tPA 59 peripheral sensory neuropathy 59 #mg dosing group 59 left ventricular systolic 59 A1c levels 59 myocardial reperfusion 59 comparator arm 59 GnRH agonist 59 microbiological eradication 59 logistic regression model 59 cerebral ischemia 59 ≥ 59 HbA 1c 59 MMSE scores 59 cardioembolic 59 cholecystitis 59 ischaemia 59 Target Lesion Revascularization TLR 59 serum creatinine levels 59 unresectable HCC 59 elevated transaminases 59 prospective multicenter randomized 59 coronary stenoses 59 necrotizing pancreatitis 59 Endothelial dysfunction 59 unfractionated heparin UFH 59 macrovascular 59 non squamous NSCLC 59 variceal hemorrhage 59 crossclamp 59 recombinant tissue plasminogen 59 atrophic gastritis 59 resynchronization therapy 59 multivessel disease 59 VUR 59 vaso occlusive crisis 59 hepatic cirrhosis 59 CYPHER R Sirolimus eluting 59 postoperative infection 59 Subgroup analysis 59 cGy 59 chemoradiation 59 severe hypersensitivity reactions 59 proliferative diabetic retinopathy 59 ipsilateral breast 59 FOLFOX4 59 primary percutaneous coronary 59 Acute Myocardial Infarction 59 gadolinium enhanced 59 IIIa inhibitor 59 p = #.# [004] 59 electrical cardioversion 59 Tasigna prolongs 59 acute coronary syndrome 59 8mg/kg 59 fluticasone salmeterol 59 log# reduction 59 bypass grafting 59 Renal dysfunction 59 5-FU/LV 59 fibrinolytic therapy 59 symptomatic DVT 59 QT prolongation 59 ventricular tachycardia 59 serum estradiol 59 MCyR 59 VaD 59 undergone radical prostatectomy 59 clopidogrel pretreatment 59 colorectal carcinoma 59 leukemia AML 59 atherogenic dyslipidemia 59 recurrent genital herpes 59 amoxicillin clavulanate 59 systolic BP 59 liver histology 59 cyclophosphamide methotrexate 59 IV NSCLC 59 Acute renal failure 59 Afib 59 ocular toxicity 59 elevated ALT 59 lipid lowering agents 59 neurologic deficits 59 HBV infections 59 plus methotrexate 59 thyrotoxicosis 59 edifoligide 59 ECASS 59 nocturnal hypoglycemia 59 dapagliflozin plus 59 recurrent miscarriage 59 VIIBRYD 59 tumor histology 59 Pegasys plus Copegus 59 statistically significant p = 59 haemorrhagic stroke 59 CI #.#-#.# [001] 59 VADT 59 TIMI 59 nonoperative 59 anemia neutropenia 59 MetS 59 antiarrhythmic drug 59 enoxaparin 59 postoperative delirium 59 prior relapsers 59 RVOT 59 pulsatile flow 59 dysglycemia 59 serum calcium levels 59 carcinoids 59 placebo controlled clinical 59 somatostatin analog 59 concomitant medications 59 nonfatal myocardial infarctions 59 R0 resection 59 onset diabetes mellitus 59 neurologic dysfunction 59 RAPTIVA 59 colorectal adenomas 59 circulating EPCs 59 lymphocyte count 59 elevated troponin 59 nonfatal cardiovascular 59 bacteremia 59 anthracycline taxane 59 neoadjuvant therapy 59 intestinal metaplasia 59 prednisone prednisolone 59 infarction STEMI 59 Myocardial Infarction 59 CK MB 59 spontaneous bacterial peritonitis 58 undetectable HBV DNA 58 CRp 58 pooled comparator 58 NIH CPSI 58 LOVENOX 58 heparin induced thrombocytopenia 58 postoperative infections 58 clinico pathological 58 parkinsonian symptoms 58 tacrolimus ointment 58 radioiodine therapy 58 brain metastases 58 virologic response EVR 58 unfractionated heparin 58 underwent radical prostatectomy 58 noninferior 58 postmenopausal osteoporotic women 58 recurrent ischemic 58 aspartate aminotransferase AST 58 radiotherapy RT 58 HCV RESPOND 2 58 preoperative radiotherapy 58 HNSCC 58 venous thrombosis 58 Asymptomatic 58 repolarization 58 bowel resection 58 dose cohort 58 preterm deliveries 58 clinically meaningful differences 58 diabetes mellitus DM 58 papillary renal cell carcinoma 58 visceral metastases 58 lipid lowering drugs 58 basal cell carcinoma BCC 58 macrovascular disease 58 nondiabetics 58 vertebral fractures 58 Natalizumab 58 argatroban 58 #mg BID [003] 58 onset seizures 58 artery reclogging 58 reperfusion 58 occlusive disease 58 TNF antagonist 58 leukopenia 58 dosing cohorts 58 stable angina 58 intravesical therapy 58 VATS lobectomy 58 atherosclerotic disease 58 angioplasty stenting 58 confidence intervals CIs 58 oral antidiabetic medication 58 placebo p = 58 μmol L 58 stage IIIb IV 58 carotid artery stenting